Tracer library / [177Lu]Lu-LNC1010
[177Lu]Lu-LNC1010
Also written as [Lu-177]Lu-LNC1010; Lu-177-LNC1010
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 0
What it is
- Compound class
- SSTR2-targeting somatostatin analog peptide with Evans blue albumin-binding moiety (long-acting somatostatin analog)
- Target / mechanism
- SSTR2 agonist (somatostatin receptor subtype 2) PMID 40177560
- Clinical application
- Peptide receptor radionuclide therapy (PRRT) in patients with advanced/metastatic neuroendocrine tumors PMID 40177560
- Theranostic pair
- —
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
Need this precursor?We can point you to suppliers for [177Lu]Lu-LNC1010, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 40177560: 'we presented the first-in-human dose escalation study of 177Lu-LNC1010 in patients with advanced/metastatic NETs'. | Stage 30 (2026-09-18): Stage was 'first-in-human'; normalised to 'Clinical research', original wording kept here.